51 research outputs found
How to Train yourself to be Healthier by Best Breathing!
Breathing is so natural that the "best way to breathe" has never been identified or promoted as such. Having episodes of life-threatening laryngospasm prompted research and study on breathing, resulting in the discovery that nasal inhaling is "best" by shutting one's mouth and concentrating on getting more oxygenation. "SAM More Oxygen" describes the "best way to breathe: SHUT your mouth. AIR in thru nose. MOUTH exhale or stay shut or cough harshly to clear throat and lungs" (but when doing a series of SAMs, cough harshly every third and fourth time to help clean your lungs and larynx)." The discovery occurred while in laryngospasm. Intensely aware of the miserable duration of previous barely effective horrible mouth clearing trying-to-breathe efforts, a conscious decision of "I am not going to go thru this again because it is torture", the mouth was shut against all natural impulses to use mouth breathing to clear my choking laryngospasm; and, amazingly, air inhalation thru the nose occurred enabling a strong cough which opened the airway; repeating the sequence many times enabled calmer more efficient return to normal breathing. The process was quickly called "SAM" and it worked every time ever since. It went into medical publication and many grateful letters were received from people who found it giving relief never before as fast or effective. Since then, research and study of breathing clearly shows the SAM More Oxygen will help many medical problems and maintain good health. But you need to practice it over and over to remember to do it. Regular breathing automatically returns but it is not "best breathing." When relaxing watching T.V. or on your computer, best breathe by gentle SAMs. Do a few when you wake up every morning--get a little more oxygen to help wake up and energize for the day. Remind each other too to SAMMO
Global phylogeography and ancient evolution of the widespread human gut virus crAssphage
Microbiomes are vast communities of microorganisms and viruses that populate all natural ecosystems. Viruses have been considered to be the most variable component of microbiomes, as supported by virome surveys and examples of high genomic mosaicism. However, recent evidence suggests that the human gut virome is remarkably stable compared with that of other environments. Here, we investigate the origin, evolution and epidemiology of crAssphage, a widespread human gut virus. Through a global collaboration, we obtained DNA sequences of crAssphage from more than one-third of the world's countries and showed that the phylogeography of crAssphage is locally clustered within countries, cities and individuals. We also found fully colinear crAssphage-like genomes in both Old-World and New-World primates, suggesting that the association of crAssphage with primates may be millions of years old. Finally, by exploiting a large cohort of more than 1,000 individuals, we tested whether crAssphage is associated with bacterial taxonomic groups of the gut microbiome, diverse human health parameters and a wide range of dietary factors. We identified strong correlations with different clades of bacteria that are related to Bacteroidetes and weak associations with several diet categories, but no significant association with health or disease. We conclude that crAssphage is a benign cosmopolitan virus that may have coevolved with the human lineage and is an integral part of the normal human gut virome
Tarteso. Nuevas Fronteras (I)
El presente volumen recoge las contribuciones presentadas al II Congreso Internacional sobre Tarteso, Nuevas Fronteras, que tuvo lugar en MeÌrida entre los diÌas 17 y 19 de noviembre de 2021. Su lectura permite un viaje desde el extremo oriental del MediterraÌneo hasta el suroeste de la peniÌnsula ibeÌrica, mostrando las diversas realidades histoÌricas acontecidas en este territorio durante la I Edad del Hierro. El objetivo de esta publicacioÌn es mostrar la situacioÌn que atravesaba el MediterraÌneo durante los anÌos de surgimiento y desarrollo de la cultura tarteÌsica para asiÌ comprender mejor la formacioÌn y evolucioÌn de dicha cultura.
El conocimiento de Tarteso ha evolucionado sensiblemente en la uÌltima deÌcada, desde la celebracioÌn y publicacioÌn de las actas del I Congreso Internacional, Tarteso. El emporio del metal (Almuzara, 2013). La incorporacioÌn de nuevas voces y visiones enfocadas al conocimiento de la protohistoria peninsular, asiÌ como de algunos temas nunca antes abordados en el conocimiento de Tarteso, permiten presentar en este volumen una visioÌn renovada, donde destaca la incorporacioÌn de unos nuevos liÌmites territoriales para esta cultura.Esta publicaciĂłn se ha beneficiado de las siguientes ayudas para su financiaciĂłn:
Proyecto de InvestigaciĂłn del Plan Nacional I+D+i: âConstruyendo Tarteso 2.0: anĂĄlisis constructivo, espacial y territorial de un modelo arquitectĂłnico en el valle medio del Guadianaâ (PID2019-108180GB- I00), financiado por MCIN AEI/10.13039/501100011033). SubvenciĂłn global de la SecretarĂa General de Ciencia, TecnologĂa, InnovaciĂłn y Universidad de la Junta de Extremadura al Instituto de ArqueologĂa.Peer reviewe
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution
APOBEC3 enzymes are cytosine deaminases implicated in cancer. Precisely when APOBEC3 expression is induced during cancer development remains to be defined. Here we show that specific APOBEC3 genes are upregulated in breast DCIS, and in pre-invasive lung cancer lesions coincident with cellular proliferation. We observe evidence of APOBEC3-mediated subclonal mutagenesis propagated from TRACERx pre-invasive to invasive NSCLC lesions. We find that APOBEC3B exacerbates DNA replication stress and chromosomal instability through incomplete replication of genomic DNA, manifested by accumulation of mitotic ultrafine bridges and 53BP1 nuclear bodies in the G1 phase of the cell cycle. Analysis of TRACERx NSCLC clinical samples and mouse lung cancer models, revealed APOBEC3B expression driving replication stress and chromosome missegregation. We propose that APOBEC3 is functionally implicated in the onset of chromosomal instability and somatic mutational heterogeneity in pre-invasive disease, providing fuel for selection early in cancer evolution
- âŠ